UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies

Porter, JB; Shah, FT; (2010) Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies. HEMATOL ONCOL CLIN N , 24 (6) 1109 - +. 10.1016/j.hoc.2010.08.015.

Full text not available from this repository.

Abstract

Transfusional iron loading inevitably results in hepatic iron accumulation, with variable extrahepatic distribution that is typically less pronounced in sickle cell disease than in thalassemia disorders Iron chelation therapy has the goal of preventing iron-mediated tissue damage through controlling tissue iron levels, without incurring chelator-mediated toxicity Historically target levels for tissue iron control have been limited by the increased frequency of deferoxamine-mediated toxicity and low levels of iron loading With newer chelation regimes these limitations are less evident The reporting of responses to chelation therapies has typically focused on average changes in serum ferritin in patient populations This approach has three limitations First changes in serum ferritin may not reflect trends in iron balance equally in all patients or for all chelation regimens Second this provides no information about the proportion of patients likely respond Third, this gives insufficient information about iron trends in tissues such as the heart Monitoring of iron overload has advanced with the increasing use of MRI techniques to estimate iron balance (changes in liver iron concentration) and extrahepatic iron distribution (myocardial T2(star)) The term nonresponder has been increasingly used to describe individuals who fail to show a downward trend in one or more of these variables Lack of a response of an individual may result from inadequate dosing high transfusion requirement poor treatment adherence or unfavorable pharmacology of the chelation regime This article scrutinizes evidence for response rates to deferoxamine deferiprone (and combinations) and deferasirox

Type: Article
Title: Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies
DOI: 10.1016/j.hoc.2010.08.015
Keywords: Chelation, Iron, Deferiprone, Deferoxamine, Deferasirox, Thalassemia, Sickle, SICKLE-CELL-DISEASE, TRANSFUSION-DEPENDENT ANEMIAS, TRANSFERRIN-BOUND IRON, LABILE PLASMA IRON, HOMOZYGOUS BETA-THALASSEMIA, RANDOMIZED CONTROLLED-TRIAL, LONG-TERM EFFICACY, MAGNETIC-RESONANCE, MYOCARDIAL IRON, LOADED PATIENTS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/730980
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item